Acetylation of the Pro-Apoptotic Factor, p53 in the Hippocampus following Cerebral Ischemia and Modulation by Estrogen by Raz, Limor et al.
Acetylation of the Pro-Apoptotic Factor, p53 in the
Hippocampus following Cerebral Ischemia and
Modulation by Estrogen
Limor Raz
., Quan-guang Zhang
., Dong Han, Yan Dong, Liesl De Sevilla, Darrell W. Brann*
Institute of Molecular Medicine and Genetics, Georgia Health Sciences University, Augusta, Georgia, United States of America
Abstract
Background: Recent studies demonstrate that acetylation of the transcription factor, p53 on lysine
373 leads to its enhanced
stabilization/activity and increased susceptibility of cells to stress. However, it is not known whether acetylation of p53 is
altered in the hippocampus following global cerebral ischemia (GCI) or is regulated by the hormone, 17b-estradiol (17b2E2),
and thus, this study examined these issues.
Methodology/Principal Findings: The study revealed that Acetyl p53-Lysine
373 levels were markedly increased in the
hippocampal CA1 region after GCI at 3 h, 6 h and 24 h after reperfusion, an effect strongly attenuated by 17b2E2.1 7 b2E2
also enhanced interaction of p53 with the ubiquitin ligase, Mdm2, increased ubiquitination of p53, and induced its down-
regulation, as well as attenuated elevation of the p53 transcriptional target, Puma. We also observed enhanced acetylation
of p53 at a different lysine (Lys
382) at 3 h after reperfusion, and 17b2E2 also markedly attenuated this effect. Furthermore,
administration of an inhibitor of CBP/p300 acetyltransferase, which acetylates p53, was strongly neuroprotective of the CA1
region following GCI. In long-term estrogen deprived (LTED) animals, the ability of 17b2E2 to attenuate p53 acetylation was
lost, and intriguingly, Acetyl p53-Lysine
373 levels were markedly elevated in sham (non-ischemic) LTED animals. Finally,
intracerebroventricular injections of Gp91ds-Tat, a specific NADPH oxidase (NOX2) inhibitor, but not the scrambled tat
peptide control (Sc-Tat), attenuated acetylation of p53 and reduced levels of Puma following GCI.
Conclusions/Significance: The studies demonstrate that p53 undergoes enhanced acetylation in the hippocampal CA1
region following global cerebral ischemia, and that the neuroprotective agent, 17b2E2, markedly attenuates the ischemia-
induced p53 acetylation. Furthermore, following LTED, the suppressive effect of 17b2E2 on p53 acetylation is lost, and p53
acetylation increases in the hippocampus, which may explain previous reports of increased sensitivity of the hippocampus
to ischemic stress following LTED.
Citation: Raz L, Zhang Q-g, Han D, Dong Y, De Sevilla L, et al. (2011) Acetylation of the Pro-Apoptotic Factor, p53 in the Hippocampus following Cerebral
Ischemia and Modulation by Estrogen. PLoS ONE 6(10): e27039. doi:10.1371/journal.pone.0027039
Editor: Huaibin Cai, National Institute of Health, United States of America
Received April 8, 2011; Accepted October 9, 2011; Published October 26, 2011
Copyright:  2011 Raz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research was supported by a research grant (NS050730) to DWB from the National Institute of Neurological Disorders and Stroke, National
Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dbrann@georgiahealth.edu
. These authors contributed equally to this work.
Introduction
Stroke is the third leading cause of death and the number one
cause of disability in the United States [1–3]. In order to help
understand the molecular mechanisms and processes that underlie
neuronal cell death following ischemic stroke, animal models of
focal and global cerebral ischemia (GCI) have been developed
[4,5] [6,7]. The hippocampal CA1 region, an area critical for
learning and memory [8–10], is highly sensitive to damage
following GCI. Along these lines, neurons in the hippocampal
CA1 region have been shown to undergo delayed apoptotic
neuronal cell death following GCI [8,9,11]. Apoptotic neuronal
cell death has also been shown to occur in the penumbra region of
the cerebral cortex after focal cerebral ischemia [12].
P53, a pro-apoptotic factor, has been implicated to play a major
role in apoptotic neuronal cell death following cerebral ischemia
[13]. Evidence from p53 knock-out mice studies revealed reduced
neuronal cell death after GCI as compared to WT-controls [14].
In addition, pifithrin-alpha (PFTa), a p53 specific pharmacological
inhibitor, attenuated p53 nuclear transport and DNA binding,
while increasing the number of surviving neurons [15] and
promoting functional recovery following stroke [16]. In non-
neuronal cells, p53 has been implicated to induce cell death
following cell stress via both a transcriptional-dependent nuclear
mechanism, as well as a transcription-independent mechanism
involving its direct action with a subset of Bcl-2 family member
proteins in the cytosol and mitochondria. However, recent work
suggests that the apoptotic activity of p53 in neurons does not rely
on its direct action at the cytosol/mitochondria and appears to be
mediated exclusively through its transcription-dependent nuclear
functions to induce the p53 pro-apototic BH3 family gene, Puma
(p53 upregulated modulator of apoptosis) [17].
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gene that is induced by p53 transcriptional activity [18,19]. Puma
and Noxa have been implicated to directly and indirectly activate
Bax (Bcl-2-associated X protein) and Bak (Bcl-2-antagonist/killer),
resulting in permeabilization of the outer mitochondrial mem-
brane, release of cytochrome c and induction of apoptosis [20,21].
Although both Puma and Noxa have been shown to mediate
neuronal cell death, only Puma deficiency was significantly
protective against apoptosis, stressing the importance of this factor
in the apoptotic cascade [22–24]. With respect to cerebral
ischemia, work by Chan and coworkers [25] demonstrated that
cerebral ischemia induced Puma upregulation in the hippocampal
CA1 region was inhibited by the p53 inhibitor, PFTa, which was
correlated with significant neuroprotection.
Due to its critical role in inducing apoptotic cell death, there has
been intense study on the mechanisms of regulating p53 stability
and activation, including post-translational modifications. Along
these lines, recent work in cancer cells has shown that p53 activity
and stability can be enhanced by acetylation at the Lysine
373
residue (and possibly Lysine
382 residue) on the C-terminal of the
p53 protein, which leads to enhanced susceptibility of cells to stress
[26–30]. This activation and acetylation of p53 is achieved by the
CBP/p300 family of acetyl transferases [31–33]. A role for p53
acetylation in enhancing apoptosis of cortical neurons in vitro after
exposure to various cell stressors has also been reported [34,35].
However, it is currently unknown whether p53 acetylation state is
altered in the brain in vivo after cerebral ischemia. Since a change
in the acetylation state of p53 following cerebral ischemia could
affect its stability and activity and influence neuronal susceptibility
to ischemic stress, a major goal of the current study was to address
this key deficit in our knowledge.
Previous work by our group and others has shown that the
steroid hormone, 17b2Estradiol (17b2E2) can exert potent anti-
apoptotic and neuroprotective effects in the hippocampal CA1
region following GCI, in part through an anti-oxidant effect to
attenuate activation of NADPH oxidase and ROS generation
[36,37]. Thus, an additional goal of our studies was to determine
whether 17b2E2 and NADPH oxidase play a critical role in
regulating p53 acetylation and corresponding induction of p53-
regulated factors in the hippocampus following cerebral ischemia.
Methods
Induction of Global Cerebral Ischemia
Adult Sprague-Dawley female rats (3 months of age) were
bilaterally ovariectomized (OVX) and immediately implanted with
placebo (Pla) or 17b-estradiol (17b2E2) Alzet minipumps
(0.025 mg; 14–21 day release), producing a low physiological
diestrus I level of 10–15 pg/ml of 17b2E2 in the blood [10]. In
some animals, long-term 17b2E2 deprivation was performed in
which the animals were ovariectomized and 10 weeks later (10 W),
placebo or 17b2E2 minipumps were implanted as previously
described [36]. A 4-vessel occlusion (4-VO) model of global
cerebral ischemia (GCI) was performed one week after initiation of
17b2E2 replacement, as described previously [36,38]. GCI is a
well known model of delayed neuronal cell death in which
hippocampal CA1 pyramidal neurons are highly susceptible to
damage and cell death [11]. Briefly, for induction of GCI, animals
were first anesthetized with chloral hydrate (350 mg/kg, i.p.). The
vertebral arteries were then electrocauterized and the common
carotid arteries (CCA) were exposed. Wound clips were then used
to close the incision and the rats were allowed a 24 h recovery
period. Following 24 h, the animals were anesthetized using 3%
isoflurane anesthesia and the CCA were re-exposed and clipped
via aneurysm clips. GCI occlusion was performed for 10 min.
duration. Rats which lost their righting reflex within 30 sec. and
whose pupils were dilated and unresponsive to light during
ischemia were selected for the experiments. Carotid artery blood
flow was restored by releasing the clips and allowing reperfusion.
Rectal temperature was maintained at 37uC using a thermal
blanket throughout the experiment and 2 h thereafter. Sham
controls underwent the same surgical exposure procedures, except
that the arteries were not occluded. All procedures were approved
by the Georgia Health Science University institutional committee
for care and use of animals (AUP# 09-03-174) and were in
accordance with National Institutes of Health guidelines.
Drug Administration
To determine whether crosstalk occurs between NADPH
oxidase-induced membrane superoxide (O2
2) production and
downstream pro-apoptotic factors, Gp91ds-Tat, a competitive
NOX2 inhibitor and its scrambled peptide control were used.
Gp91ds-Tat is a competitive inhibitor consisting of a 9 amino-acid
peptide sequence of the p47phox subunit docking site on NOX2,
thereby preventing p47phox from forming a complex with NOX2
and activating the enzyme [39]. Gp91ds-Tat and the scrambled
peptide control were administered into the lateral ventricles of the
hippocampus CA1, at a dose of 100 ng in 5 ml. The dose of
gp91ds-Tat was chosen based on previous studies by our
laboratory showing its effectiveness in inhibiting NADPH oxidase
and lack of side effects [36]. For intracerebroventricular (icv)
injections, anesthetized rats were placed on ear bars of a
stereotaxic instrument. Drug infusion was performed using a
stepper motorized microsyringe (Stoelting, Wood Dale, IL, USA)
at a rate of 1 mL/min into the cerebral ventricle (from the bregma:
anteroposterior,60.8 mm; lateral, 1.5 mm; depth, 3.5 mm).
When necessary, curcumin (200 mg/kg, sc-294110, Santa Cruz
Biotechnology, Inc.) or DMSO vehicle was injected intraperito-
neally, 30 min prior to the induction of GCI.
DAB Staining
Sections for DAB staining were incubated with 10% normal
donkey serum in PBS containing 0.1% Triton X-100 and 0.3%
H2O2 to block nonspecific surfaces for 1 h at room temperature.
Sections were then incubated with the primary antibodies
overnight at 4u Celsius (Cu) in PBS containing 0.1% Triton X-
100. The antibodies used were as follows: goat anti-Noxa (1:200,
Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-
Acetyl p53-lysine
373 (1:200, Millipore, Billerica, MA). Afterwards,
sections were washed with the same buffer, followed by incubation
with a secondary biotinylated anti-goat or rabbit antibodies
(Molecular Probes, Eugene, OR, USA) at a dilution of 1:500 in
PBS containing 0.1% Triton X-100 for 1 h at room temperature.
Sections were then washed, followed by incubation with ABC
reagents for 1 h at room temperature in the same buffer. Sections
were rinsed with the same buffer and incubated with DAB reagent
for 2–10 min., according to the instructions of the manufacturer
(Vector Laboratories). Sections were briefly washed with distilled
water and dehydrated in graded alcohols, cleared in xylene, and
mounted using xylene-based mounting medium following DAB
staining. Images were captured on an Axiophot-2 visible
microscope using an AxioVision4Ac software system (Carl Zeiss,
Germany) at a magnification of 10X or 40X, respectively. The
number of NOXA or Acetyl p53-lysine
373-positive cells was
counted, as described previously [36]. Briefly, for quantitative
analyses, neurons which stained positively for Noxa or acetylated
p53 were counted bilaterally per 250 mm length of medial CA1
pyramidal cell layer, in four to five sections per animal to provide a
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data in each group (n=5–6 animals), and statistical analysis was
performed as described below.
Double Immunofluorescence Staining
Coronal sections were incubated with 10% normal donkey
serum for 1 h at room temperature in PBS containing 0.1% Triton
X-100, followed by incubation with appropriate primary antibod-
ies overnight at 4uC in the same buffer. The following primary
antibodies were used in different combinations: rabbit anti-acetyl
p53-Lysine
373, mouse anti-NeuN (1:200, Millipore, Billerica, MA)
and rabbit anti-Puma a/b (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA). After primary antibody incubation, sections
were washed and incubated with Alexa Fluor594/647 donkey
anti-rabbit or Alexa-Fluor488/594 donkey anti-mouse secondary
antibodies (1:500; Invitrogen Corporation, Carlsbad, CA), respec-
tively, for a period of 1 h at room temperature. Sections were
washed with buffer, followed by PBS and then briefly, with water.
Sections were mounted using water-based mounting medium with
anti-fading agents (Biomeda, Fisher Scientific, Pittsburgh, PA).
Negative experimental controls were incorporated by omission of
the primary antibody, thus confirming the absence of non-specific
immunofluorescent staining, cross-immunostaining, or fluores-
cence bleed-through.
Confocal Microscopy and Image Analysis
Double-labeled images were captured on an LSM510 Meta
confocal laser microscope (Carl Zeiss, Germany) using a 40X oil-
immersion Neofluor objective with a 1.3 numerical aperture. The
image size was set at 102461024 pixels, as previously published
[40]. Excitation/emission laser filters settings were used for various
chromophores as follows: argon/2 laser was used for Alexa
Fluor488, with excitation maximum at 490 nm and emission in
the range of 505–530 nm and HeNe1 laser was used for Alexa
Fluor594, with excitation maximum at 543 nm and emission in
the range of 568–615 nm. The captured images were viewed and
analyzed using LSM510 Meta imaging software.
Brain Homogenates and Subcellular Fractionations
For brain tissue preparation, rats were sacrificed under
isoflurane anesthesia after GCI, at the timepoints described in
the figure legends. The CA1 region of the hippocampus was
micro-dissected bilaterally from the hippocampal fissure and
immediately frozen in liquid nitrogen. The protocol for obtaining
total tissue lysates was as follows: tissue homogenization was
performed with a Teflon-glass homogenizer in ice cold homog-
enization medium consisting of 50 mM HEPES (pH 7.4),
150 mM NaCl, 12 mM b-glycerophosphate, 3 mM dithiotheitol
(DTT), 2 mM sodium orthovanadate (Na3VO4), 1 mM EGTA,
1 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1%
Triton X-100, and 10 mg/ml each of aprotinin, leupeptin, and
pepstatin A. The homogenates were centrifuged at 15,0006g for
30 min. at 4uC and total lysate supernatants were collected and
stored at 280uC for later use. Protein concentrations were
determined by a Lowry protein assay kit with bovine serum
albumin utilized as a standard.
Co-Immunoprecipitation
For co-immunoprecipitation (Co-IP), total fractions (each
containing 200 mg of protein) obtained at the ischemic reperfusion
timepoints described in the figure legends, were diluted 4-folds
with 500 mL of HEPES buffer containing the following reagents:
50 mM HEPES (pH7.4), 150 mM NaCl, 10% glycerol, 1% Triton
X-100, and 1 mM each of EGTA, EDTA, PMSF and Na3VO4.
The samples were then pre-incubated with 20 ml protein A/G and
centrifuged to remove non-specific protein bound to the A/G
protein. The supernatant was incubated with 5 mg of mouse anti-
p53 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
and mixed for 4 h at 4uC. After the addition of Protein A/G-
sepharose, the mixture was incubated at 4uC for 2 additional
hours. Samples were washed three times with HEPES buffer and
eluted by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) loading buffer, then boiled for 5 min.
Western Blots
Western blotting was performed on total lysates collected post-
reperfusion, as described in the relevant figure legends and in our
laboratory publications [10]. The antibodies used were as follows:
Rabbit anti-Acetyl p53 specifically recognizing p53 acetylation at
Lysine
373 by p300, (1:150, Millipore, Billerica, MA), Rabbit anti-
Acetyl-p53 (Lys
382, 1:200, Cell Signaling Technology, Inc.),
Rabbit anti-Actin (1:300, Sigma-Aldrich, St. Louis, MO), rabbit
anti-Mdm2 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit anti-p53 (1:200, Cell Signaling Technology, Inc., MA),
rabbit anti-Puma a/b (1:150, Santa Cruz Biotechnology, Santa
Cruz, CA) and mouse anti-Ubiquitin (Santa Cruz Biotechnology,
Santa Cruz, CA). The membrane was then washed with T-TBS to
remove unbound antibody, followed by incubation with Alexa
Fluor 680 goat anti-rabbit/mouse IgG and Alexa Fluor 680
donkey anti-rabbit/goat IgG for 1–2 h at room temperature.
Bound proteins were visualized using the Odyssey Imaging System
(LI-COR Bioscience, Lincoln, NB) and semi-quantitative analysis
of the bands was performed with Image J analysis software
(Version 1.30 v; NIH, USA). Band densities for the indicated
proteins were normalized and expressed relative to actin house-
keeping gene total protein or total p53 protein, as indicated in the
figures. Normalized means were then expressed as fold change of
the corresponding value for control (sham operated) animals. A
Mean6SE was calculated from the data, from 4–5 animals per
treatment group for graphical presentation and statistical com-
parison.
Real Time-PCR
Total RNA from the female rat hippocampal CA1 region was
isolated following ischemic reperfusion as described in the
corresponding figure legends and LightCycler RNA Amplification
Kit SYBR Green I (Roche Applied Science, IN) was utilized. A
negative control, which consisted of pooled total RNA run in the
RT-PCR without RT added, was also included. Actin was used as
a loading control. Five hundred nanograms of the RT reactions
were used for the PCR, with the following primer sets to identify
p53: forward primer 5’- TCT CCC CAG CAA AAG AAA AA - 3’
and reverse primer 5’ – CTT CGG GTA GCT GGA GTG AG –
3’. PCR reactions were conducted under the following conditions:
35 cycles at 95uC for 5 min, followed by 65uC for 30 min and
72uC for 3 min. at an annealing temperature of 65uC and 4 mM
of MgCl2. A total of 5 mL of the PCR product was electropho-
resed, visualized with ethidium bromide, and photographed for
documentation. A standard curve was generated and results were
quantified accordingly in rg/mL.
Statistical Evaluation
Four to five animals were used per treatment group. All values
were expressed as the means6SE. Statistical analysis of the results
was carried out by One-Way Analysis of Variance (ANOVA),
followed by the Student-Newman–Keuls post-hoc test to determine
group differences. When groups were compared to a control group
Acetylation of p53
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ANOVA. Statistical significance was accepted at the 95% confidence
level (p,0.05). Data was expressed as mean6standard error (SE).
Results
17b2E2 Attenuates Cerebral Ischemia-Induced Elevation
of p53 and Acetyl p53-Lysine
373 Levels in the
Hippocampal CA1 Region
Figure 1A shows that p53 levels in the hippocampal CA1
region are significantly increased at 6 h and 1 d after cerebral
ischemia (Pla) as compared to sham controls. P53 levels at 3 h
after reperfusion showed a pattern for elevation, which, however,
was not statistically significant. In addition, 17b2E2 treatment
significantly attenuated p53 elevation at 3 h, 6 h and 24 h
after ischemic reperfusion (Fig. 1A). Figure 1B shows Acetyl
p53-Lysine
373 levels (expressed as ratio of Acetyl p53-Lysine
373/
p53) in the hippocampal CA1 region at various time-points after
GCI. The data shows that Acetyl p53-Lysine
373 levels increase
significantly in the hippocampal CA1 region at all time-points
examined after GCI (3 h, 6 h and 24 h) as compared to sham
controls. In addition, 17b2E2 treatment significantly attenuated
ischemia-induced Acetyl p53-Lysine
373 levels at all time-points
after GCI reperfusion, with the most robust effect seen at 3 h
following ischemic reperfusion (Fig. 1B). To determine in which
cell types acetylation of p53 occurred, we performed double
immunohistochemistry on hippocampal CA1 sections collected at
24 h after GCI for the neuronal marker, NeuN (red), and Acetyl
p53-Lysine
373 (green) (Fig. 1C). The results show that Acetyl p53-
Lysine
373 staining is highly co-localized in neurons, and confirm
the ischemic reperfusion elevation of Acetyl p53-Lysine
373 levels in
the CA1 region after cerebral ischemia (Pla vs. Sham), and the
Figure 1. P53 levels and acetylation of p53 on Lysine
373 are increased in the hippocampus following global cerebral ischemia and
attenuated by 17b-estradiol. (A & B) Homogenates obtained from the hippocampus CA1 at 3 h, 6 h and 24 h after reperfusion were subjected to
Western blot analyses to examine the temporal expression of p53 (A) and Acetyl p53-Lys
373 (B). Actin bands represent loading control. Data is
expressed as fold differences as compared to sham (A) and Acetyl p53/p53 protein ratio expressed in relative units (B) from four to five animals.
*p,0.05 vs. Sham, #p,0.05 vs. Pla control; S=Sham, P=Pla, E=E2. (C) Representative hippocampal CA1 sections were double labeled with the
neuronal marker NeuN (red) and Acetyl p53 (green) at 24 h following ischemic reperfusion. Merged images represent acetylated p53 in pyramidal
CA1 neurons of the hippocampus. Magnification 40X. n=4–5 animals per treatment group.
doi:10.1371/journal.pone.0027039.g001
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compared to placebo-treated (Pla) controls at 24 h following
cerebral ischemia (Fig. 1C). It should be mentioned that the
regulatory effect of 17b2E2 on acetylation of p53 at Lys
373 was
only observed in animals following elevation by cerebral ischemia,
as we observed no regulation by 17b2E2 of basal Acetyl p53-
Lysine
373 levels in non-ischemic sham controls (Figure S1A).
Estrogen attenuates p53 acetylation at Lysine
382 shortly
after ischemic reperfusion
Previous studies have shown that p53 can also be acetylated on
Lysine
382, and that this increases stability of p53 [41]. We
therefore examined whether Acetyl p53-Lysine
382 levels increase
in the hippocampal CA1 region at 3 h after GCI (the time when
Acetyl p53-Lysine
373 displayed peak levels) and determined
whether 17b2E2 similarly attenuates acetylation of p53 at the
Lys
382 site. The results of the study revealed a marked increase in
Acetyl p53-Lysine
382 levels in the hippocampal CA1 region of
placebo (Pla)-treated animals at 3 h after GCI as compared to
sham controls. In addition, 17b2E2 significantly attenuated the
elevation of Acetyl p53-Lysine
382 levels (Figure S1B). Note that
total p53 levels remained unchanged in all treatment groups
examined, and that 17b2E2 had no effect on basal Acetyl p53-
Lysine
382 levels in non-ischemic sham animals.
17b-Estradiol Down-Regulates BH3 Family Members
Puma and Noxa Following Ischemia
We next examined the expression of the downstream p53
transcriptional target proteins, Puma and Noxa. In addition, we
performed double immunohistochemistry on coronal hippocampal
CA1 sections from the 24 h time-point for the neuronal marker,
NeuN, (red) and Puma (green) to determine whether Puma exhibits
neuronal localization and is regulated by 17b2E2. As shown in
Fig. 2A, representative images revealed Puma predominantly
localized in pyramidal neurons of the hippocampus CA1 region in
all treatment groups studied. Of significant interest, the results
revealed a robust elevation of Puma immunoreactive staining in
placebo (Pla) animals following GCI as compared to sham controls,
Figure 2. 17b-Estradiol attenuates downstream pro-apoptotic BH3 family members, Puma and Noxa, in the CA1 following ischemia.
(A) Hippocampal CA1 sections were double stained for NeuN neuronal marker (red) and Puma (green) at 24 h following global cerebral ischemia.
Merged images depict Puma neuronal localization in the CA1 region of the hippocampus. Magnification 40X. (B) Western blot using anti-Puma
antibody shows Puma protein expression at 24 h following ischemic reperfusion. Actin bands represent loading control. Data is expressed as fold
differences in comparison to sham from four to five animals. *p,0.05 vs. Sham,
#p,0.05 vs. Pla; Pla=Placebo, E2=17b2E2. (C) Effect of 17b2E2
treatment on Noxa protein expression at 24 h reperfusion timepoint following cerebral ischemia. Representative photomicrographs of DAB staining
obtained at a magnification of 10X (left panels). Semi-quantitative analysis of Noxa staining expressed as the number of Noxa-positive cells per
250 mm area obtained from 4–5 hippocampal sections per animal (right panels). *p,0.05 vs. Sham,
#p,0.05 vs. Pla. n=4–5 animals per treatment
group.
doi:10.1371/journal.pone.0027039.g002
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Figure 2B shows Western blot analysis of total Puma protein levels
in hippocampal CA1 region samples collected at 24 h after GCI. As
shown in Fig. 2B, similar to the immunostaining results, Western
blot analysis revealed that Puma levels are significantly elevated in
placebo (Pla) animals after GCI as compared to sham controls, and
that 17b2E2 (E2) treatment significantly attenuated the elevation of
Puma. In Figure 2C, we examined an additional p53-induced
BH3family pro-apoptoticprotein,Noxa,viaDABimmunostaining.
As shown in Fig. 2C (left panel), representative photomicro-
graphs of Noxa immunostaining reveal a similar pattern to that of
Puma up-regulation in ischemic animals, and 17b2E2 treatment
markedly attenuating the ischemia-induced up-regulation of Noxa.
Semi-quantitative analysis of the Noxa staining results through
counting of the number of Noxa-positive cells in the hippocampal
CA1 sections confirmed an elevation of Noxa-positive cells in the
placebo (Pla) group as compared to the sham controls, and a strong
attenuation of the number of Noxa-positive cells by 17b2E2 (E2)
(Fig. 2C, right panel).
17b2E2 Enhances Both the Interaction of the Ubiquitin
Ligase, Mdm2 with p53 and the Ubiquitination of p53
Following GCI
It has been reported that deacetylation of p53 at Lysine
373
decreases the stability of p53 and leads to its ubiquitination and
degradation [42,43]. The E3 ubiquitin ligase, Mdm2, has been
implicated to be an important factor responsible for ubiquitination
of p53 [44,45]. We thus examined whether Mdm2 interaction with
p53 and ubiquitination of p53 in the hippocampal CA1 region is
modulated by 17b2E2 following GCI. We also examined p53
mRNA levels to rule out that p53 changes after GCI or 17b2E2
treatment were due to changes in p53 gene expression. Figure 3A
illustrates the results of examination of p53 gene expression in the
Figure 3. 17b-Estradiol enhances p53 interaction with Mdm2 and p53 ubiquitination. (A) P53 mRNA levels remain unchanged in the
hippocampus CA1 at 6 h and 24 h following cerebral ischemia as measured by real-time RT-PCR. (B)1 7 b2E2 increases p53-ubiquitin interactions and
decreases p53 levels at 24 h after GCI reperfusion. *p,0.05 vs. Pla. (C) 17b2E2 increases p53-Mdm2 binding two fold as compared to placebo-treated
control levels at 6 h after cerebral ischemic injury. P53 protein expression level serves as Co-IP control. *p,0.05 vs. Pla. Pla=Placebo, E2=17b2E2..
n=4–5 animals per treatment group.
doi:10.1371/journal.pone.0027039.g003
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(RT)-PCR. As shown in Fig. 3A, neither ischemia (Pla) nor
17b2E2 (E2) treatment significantly affected p53 gene expression in
the hippocampal CA1 region. Actin, used as a loading experimental
control, revealed equal loading on the RT-PCR gel (data not
shown). We next examined ubiquitination of p53 by co-immuno-
precipitated (Co-IP) of p53 and immunoblotting for ubiquitin at the
24 h time-point after reperfusion using total hippocampal CA1
region samples. The results showed that 17b2E2 treatment
significantly increases p53 ubiquitination as compared to placebo-
treated or sham control animals (Fig. 3B). Co-IPs were also
performed examining p53-Mdm2 interaction in the hippocampal
CA1 region after GCI (Fig. 3C). As shown in Fig. 3C, the Pla
group had a pattern for a decrease of p53-Mdm2 interaction that
correlated with an increase of p53 protein levels. In contrast,
17b2E2-treated animals had a significant enhancement of p53-
Mdm2 interaction in the CA1 region, which correlated with a
significant decrease in p53 protein levels (Fig. 3C).
NOX2 NADPH Oxidase Inhibition Attenuates Acetyl p53/
p53 Ratio and Puma Levels after GCI
Previous work by our laboratory revealed that 17b2E2 can
attenuate NOX2 NADPH oxidase-induced superoxide (O2
2)
production, and that administration of a competitive NOX2
inhibitor, Gp91ds-Tat, is strongly neuroprotective against GCI-
induced neuronal damage in the hippocampal CA1 region [36].
We therefore hypothesized that NADPH oxidase-induced ROS
may regulate p53 and its acetylation following GCI. To address
this possibility, we used icv injections of the specific NOX2
inhibitor, Gp91ds-Tat. As a control, we used a scrambled tat
peptide (Sc-Tat) that does not exert inhibitory effects on NADPH
oxidase. Pro-apoptotic p53 levels remained unchanged in all of the
treatment groups examined, further validating our previous
observations (Figure 4). When compared to scrambled-tat control
peptide-treated animals, Gp91ds-Tat-treated animals had a
significant attenuation of GCI-induced elevation of Acetyl p53
(expressed as an acetyl p53/p53 ratio) and a significant decrease in
Puma protein levels in the hippocampal CA1 region at 3 h after
GCI reperfusion, a time of peak NADPH oxidase activation
following GCI [36]. This finding suggests that NADPH oxidase
activation potentially contributes to cerebral ischemia-induced
elevation of acetyl p53 and downstream Puma expression
following GCI (Figure 4).
Long-term Estrogen Deprivation Promotes p53
Acetylation and Activation in the Nucleus of
Hippocampal CA1 Cells after Global Cerebral Ischemia
Finally, our group recently demonstrated that 17b2E2
neuroprotection against GCI is lost if it is preceded by a prolonged
period of 17b2E2 deprivation (e.g. 10 weeks ovariectomy) [36].
We thus examined whether long-term estrogen deprivation leads
to a loss of 17b2E2 ability to attenuate Acetyl p53-lysine
373 levels
in the hippocampal CA1 region after GCI. We therefore
compared animals treated immediately with 17b2E2 (Imm)t o
those in which 17b2E2 treatment was initiated after a long term
period of 17b2E2 deprivation (e.g. treated 10 weeks after
ovariectomy) (10 W)( Figure 5A, 5B). Representative photomi-
crographs of the hippocampal CA region from the 24 h time-point
after GCI from the various groups are presented in Fig. 5A, and
semi-quantitative analysis of number of Acetyl p53-lysine
373
positive cells are presented in Fig. 5B. As shown in Fig 5A,
5B, in the immediate (Imm) treatment paradigm, Pla-treated
animals had robust staining and number of Acetyl p53-lysine
373
positive cells in the CA1 region as compared to sham controls,
while immediate 17b2E2-treatment caused a profound reduction
in the staining and number of Acetyl p53-lysine
373 positive cells. In
contrast, in long-term E2 deprived (10 W) sham animals, there was
robust Acetyl p53 staining and a high number of Acetyl p53-
lysine
373-positive cells (Fig. 5A, 5B). In addition, long-term E2
deprived (10 W) Pla animals also showed robust Acetyl p53
staining and a high number of Acetyl p53-lysine
373 positive cells in
the hippocampal CA1 region, which was not significantly different
from the 10 W sham controls. Interestingly, the ability of 17b2E2
to attenuate Acetyl p53 staining and number of Acetyl p53-
lysine
373-positive cells was completely lost in the long-term E2
deprived animals (Fig. 5A, 5B).
Inhibition of CBP/p300 acetyltransferase is neuro-
protective of the hippocampus CA1 following global cerebral
ischemia. We next examined whether inhibition of CBP/p300
acetyltranferases, which acetylate p53, would exert neuroprotection
against GCI. To examine this question, we utilized the selective
CBP/p300 acetyltransferase inhibitor, curcumin [31,32]. As shown
in Figure 6A and 6B, administration of curcumin 20 minutes prior
toGCIwasstronglyneuroprotectiveinthehippocampalCA1region,
as evidenced by preservation of NeuN-stained surviving cells and a
decrease in TUNEL-positive cells in the CA1 region at 7 days after
GCI.
Discussion
The current study advances the field by demonstrating that p53
undergoes enhanced acetylation on Lysine
373 and Lysine
382 in the
hippocampal CA1 region following global cerebral ischemia.
Acetylation of p53 at Lysine
373 and Lysine
382 has been shown to
enhance stability and pro-apoptotic activity of p53, while
increasing sensitivity to cell stress [27–30,41,46]. Thus, our study
suggests that post-translational modification of p53 by acetylation
Figure 4. NADPH oxidase inhibition attenuates Acetyl p53-
Lysine
373 levels and Puma levels following GCI. Inhibition of
NADPH oxidase using the competitive NOX2 inhibitor, Gp91ds-Tat
(Gp91), reduces Acetyl p53-Lysine
373 levels, while diminishing Puma
protein levels, as compared to the scrambled tat (Sc-Tat) control group.
CA1 total lysates were collected at 3 h upon reperfusion onset and
probed with appropriate antibodies to detect protein expression in
Western blot. P53 protein expression remained unchanged. Actin was
used as a loading control. Data is represented as fold differences in
comparison to sham from four to five animals. *p,0.05 vs. Sham,
#p,0.05 vs. Sc-Tat; S=Sham.
doi:10.1371/journal.pone.0027039.g004
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p53 stability and activation following cerebral ischemia, leading to
enhanced apoptotic cell death. Our study also shows that 17b2E2
acts in the hippocampus to decrease acetylation of p53 on Lysine
373
and Lysine
382 following GCI.
It is currently unclear how 17b2E2 is able to attenuate
acetylation of p53. It is possible that the regulatory effects of
17b2E2 are mediated indirectly, through its previously reported
ability to suppress NOX2 NADPH oxidase activation [36]. Along
these lines, administration of a NOX2 inhibitor in the current
study led to inhibition of p53 acetylation following GCI. This
suggests that NOX2 activation may contribute to cerebral
ischemia-induced p53 acetylation in the brain, potentially via
induction of ROS. NADPH oxidase activation leads to generation
of superoxide, which can be converted to highly reactive and
damaging ROS such as hydroxyl ion and peroxynitrite and
contribute to oxidative stress [47]. Intriguingly, a role for oxidative
stress in regulating p53 acetylation is supported by previous in vitro
studies which showed that oxidative stress markedly enhances p53
acetylation [29,48].
Other pro-death (Lysine
317) and pro-survival (Lysine
320) acet-
ylation sites have also been implicated to regulate p53 function
and have different biological consequences [27,30]. A significant
caveat of our studies is that we only examined a couple of pro-
death acetylation sites (Lysine
373 and Lysine
382) using the
acetylated-Lysine-specific antibodies directed to the particular site
of interest. It is possible that acetylation at the other known
acetylation sites could change as well after cerebral ischemia and/
or 17b2E2 treatment, but further studies will be needed to address
this issue. In addition to acetylation, other post-translational
modifications can also influence p53 function and could be
regulated by 17b2E2. For instance, studies in breast cancer cells
revealed that 17b2E2 inhibited resveratrol-stimulated phosphor-
ylation of Serines
15, 20 and 392 of p53 and acetylation of p53 in a
concentration-and time-dependent manner, and decreased apop-
tosis [49]. To our knowledge, no one has examined whether
17b2E2 exerts a similar regulatory effect upon phosphorylation of
p53 in the brain following cerebral ischemia. Further studies are
thus needed to address this issue. Finally, it has been demonstrated
that p53 can be methylated at Lysine
372, which leads to enhanced
stability and activity of p53 [50]. Intriguingly, we found that
17b2E2 treatment significantly attenuated methylation of p53 at
Lysine
372 following global cerebral ischemia, which may contrib-
ute to decreasing stability and activity of p53 and to the overall
Figure 6. Neuroprotective effects of curcumin in the hippo-
campus CA1 following global ischemia. (A) Representative
photomicrographs of the hippocampal CA1 region showing NeuN
and TUNEL staining following 7 days of ischemic reperfusion. (B)
Quantitative summary of data (means6SE, n=6 animals per group)
indicating the number of surviving neurons and apoptotic neurons per
250 mm length of medial CA1. NeuN positive pyramidal cells containing
intact and round nuclei were counted as surviving cells. Scale
bar=50 mm, magnification 40X. *p,0.01 vs. sham and curcumin
groups. Veh=vehicle; Cur=curcumin.
doi:10.1371/journal.pone.0027039.g006
Figure 5. The ability of estrogen to suppress the elevation of Acetyl p53-Lysine
373 levels following GCI is lost in long-term estrogen
deprived animals. (A) Representative DAB images of immediate (Imm, 7 d) and 10 week (10 W) E2 deprived animals at 24 h following ischemic
reperfusion. Note that 17b2E2 attenuation of Acetyl p53-Lysine
373 levels is lost in long-term E2 deprived (10 W) animals and that there is robust p53
acetylation in all 10 W animals. Magnification 40X. (B) Semi-quantitative analysis of Acetyl p53-Lysine
373-positively stained cells in Imm (7 d) and long-
term (10 W)E 2-deprived animals, expressed as folds vs. sham in 4–5 sections. *p,0.05 vs. Sham, #p,0.05 vs. Pla or 10 W E2 group; NS=No
significant difference. n=4–5 animals per treatment group.
doi:10.1371/journal.pone.0027039.g005
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agreement with the breast cancer literature, where 17b2E2
similarly was found to reduce p53 methylation at Lysine
372
[51,52].
Our study also demonstrated the ability of 17b2E2 to regulate
the p53-induced BH3 family members, Puma and Noxa. We
showed that 17b2E2 neuroprotective properties prevented the
elevation of these factors involved in the neuronal apoptotic
pathway at 24 h after reperfusion. Work from transient GCI
studies measuring Puma expression in the hippocampus CA1 [25]
and in the cortex of MCAO ischemic animals [25] similarly
confirms Puma elevation at 24 h following ischemic reperfusion,
while the breast cancer literature provides support for 17b2E2
downregulation of Puma transcriptional activity [53]. Overex-
pression of Puma has also been shown to be sufficient to induce
Bax (Bcl-2-associated X protein)-dependent neuronal death in
cultured neuronal cells, further supporting its pro-apoptotic role in
neurons [17].
Our data also demonstrates that 17b2E2 treatment induces an
increased interaction of p53 with the E3 ubiquitin ligase, Mdm2,
which is correlated with enhanced ubiquitination and a decrease
in p53 protein levels. Interestingly, p53 acetylation sites Lysine
373
and Lysine
382 have been shown to be the same sites for MDM2
binding [54,55]. Consequently, acetylation of p53 at these sites has
been shown to result in an inability of MDM2 to bind p53 for
degradation, and thus, p53 is kept at a high level [56]. In further
support of this suggestion, administration of a histone acetylase
inhibitor that specifically enhances acetylation at these sites has
been shown to result in a significantly prolonged half-life of p53 by
decreasing p53 ubiquitination [54]. Previous work has shown that
the acetyltransferase, CBP/p300, plays a major role in acetylating
p53. Our studies showed that administration of the CBP/p300
inhibitor, curcumin, was strongly neuroprotective against GCI,
which is consistent with an important role for acetylated p53 in
neuronal damage and cell death following cerebral ischemia.
Finally, an additional interesting finding of our study was that
the ability of 17b2E2 to attenuate p53 acetylation was lost if the
17b2E2 replacement was preceded by a period of long-term
estrogen deprivation (LTED) (10 week ovariectomy). We previ-
ously showed that the neuroprotective effect of 17b2E2 in GCI is
similarly lost following LTED [36]. The loss of the ability of
17b2E2 to attenuate acetylation of p53 in the LTED animals
could potentially explain the loss of the neuroprotective effect of
17b2E2 reported previously. An additional intriguing finding was
that sham (non-ischemic) animals showed high p53 acetylation
levels in the hippocampal CA1 region following LTED. The
robust acetylation of p53 in animals following LTED suggests a
role for endogenous 17b2E2 to restrain p53 acetylation in the
hippocampus. This is intriguing, as we previously found that
LTED animals are hypersensitive to ischemic stress, and show
enhanced ischemic damage to the hippocampus following GCI [36].
This agrees with previous in vitro findings showing that acetylation
of p53 increases the susceptibility of cells to stress [28,29]. Thus, the
elevated p53 acetylation in sham LTED animals in our current
study may provide an explanation for our previous report of
enhanced susceptibility of LTED animals to ischemic stress.
In conclusion, the current study demonstrates that p53 under-
goes enhanced acetylation in the hippocampal CA1 region
following GCI, and that the neuroprotective hormone, 17b2E2,
acts to strongly suppress the acetylation of p53, leading to
ubiquitination and attenuation of p53 levels, as well as attenuation
of the p53-regulated pro-apoptotic factors, Puma and Noxa. As a
whole, the studies enhance our understanding of p53 regulation in
the brain following GCI, and suggest a potentially important
regulatory role for estrogen in the control of p53.
Supporting Information
Figure S1 A) Lack of effect of estrogen on basal Acetyl p53-
Lysine
373 levels and Puma levels in sham non-ischemic control
animals. Estrogen (E2) has no significant effect upon Acetyl p53-
Lysine
373, p53, and Puma levels in the hippocampal CA1 region of
non-ischemic sham control animals as compared to placebo (Pla)
treated animals. B) Estrogen attenuates Acetyl p53 (Lysine
382)
levels at 3 hours following ischemic reperfusion. Acetylation of p53
at Lysine
382 did not change in Pla and E2-treated shams. A
significant increase in p53 acetylation at Lysine
382 is observed in
Pla-treated animals at 3 h after ischemic reperfusion, whereas E2-
treatment significantly attenuated this elevation. Total p53 levels
remained unchanged in all treatment groups examined. *p ,0.05
vs. sham and
#p ,0.05 vs. Pla group.
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